NCT05172245 2026-03-18Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck CancerNational Cancer Institute (NCI)Phase 1 Recruiting46 enrolled
NCT05172258 2026-03-18Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckNational Cancer Institute (NCI)Phase 2 Active not recruiting52 enrolled